MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference
Rhea-AI Summary
MBX Biosciences (Nasdaq: MBX) announced that CEO Kent Hawryluk and CMO Sam Azoulay, M.D., will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025.
Presentation format: fireside chat and 1x1 meetings; time: 4:00 p.m.–4:25 p.m. ET; location: New York, NY. The presentation will be webcast live and a replay will be posted approximately two hours after the event and archived on the company website for about 90 days.
Investors can access the live webcast and replay via the events section of the MBX Biosciences investor website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MBX gained 2.93%, reflecting a moderate positive market reaction. Argus tracked a peak move of +2.1% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $36M to the company's valuation, bringing the market cap to $1.26B at that time.
Data tracked by StockTitan Argus on the day of publication.
CARMEL, Ind., Nov. 18, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present and participate in the 37th Annual Piper Sandler Healthcare Conference being held on December 2-4.
37th Annual Piper Sandler Healthcare Conference
Date: Tuesday, December 2, 2025
Format: Fireside chat and 1x1 meetings
Time: 4:00 p.m. – 4:25 p.m. ET
Location: New York, NY
The live webcast can be accessed in the events section of the MBX Biosciences website at https://investors.mbxbio.com/news-events/events. Access to the webcast replay will be available approximately two hours after the completion of the events and will be archived on the Company’s website for approximately 90 days.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism (HP) in Phase 2 development; imapextide (1416) for the treatment of post-bariatric hypoglycemia (PBH) in Phase 2 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development, as well as multiple discovery and pre-clinical obesity candidates. The Company is based in Carmel, Indiana. To learn more, please visit the Company website at https://mbxbio.com/ and follow it on LinkedIn.
Media Contact:
Cassidy McClain
Inizio Evoke Comms
cassidy.mcclain@inizioevoke.com
(619) 694-6291
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
When will MBX Biosciences (MBX) present at the Piper Sandler Healthcare Conference?
Who from MBX Biosciences will present at the December 2, 2025 MBX (MBX) session?
How can investors watch MBX Biosciences (MBX) presentation on December 2, 2025?
When will the replay of the MBX Biosciences (MBX) Piper Sandler presentation be available?
What is the format and location of MBX Biosciences (MBX) presentation at the conference?
Where on the MBX Biosciences website can I find the live webcast and replay for the December 2, 2025 event?
